LATEST

• BUSINESS RaQualia Partner Files US NDA for Tegoprazan
  January 14, 2026

• REGULATORY MHLW to Set Up Expert Panel on Using Disease Registries in Drug Development
  January 13, 2026

• REGULATORY Chuikyo Moves to Allow Special Mixed-Billing for Santen’s Myopia Drug
  January 13, 2026

• REGULATORY Japan Panel to Review AbbVie’s Aquipta, Ipsen’s Sohonos on January 23
  January 13, 2026

• BUSINESS Takeda Taps Halozyme’s Delivery Tech to Develop New Entyvio SC Formulation
  January 13, 2026

• BUSINESS Japan Heart Failure Drug Market Seen 1.5-Fold Growth by 2030: Fuji Keizai
  January 13, 2026

• BUSINESS Daito Secures China Approval for EquMet Generic
  January 13, 2026

• BUSINESS Japan Ethical Drug Sales Edge Up 0.4% in November: Crecon
  January 13, 2026

• REGULATORY MHLW Pharma Director Says Uniform Drug Price Hike “Not Realistic,” Targeted Support Preferred
  January 9, 2026

• BUSINESS Bayer/Santen to Launch Eylea Bio-AG on February 2
  January 9, 2026

• ORGANIZATION EFPIA Japan Appoints Novartis’ Pullicino as Vice Chair
  January 9, 2026

• BUSINESS Nxera Bags Japan, Select APAC Rights to Santhera’s DMD Therapy
  January 9, 2026

• BUSINESS Keio Offshoot Taps Alfresa Know-How for Cell Therapy Push, Bets on Dual iPS Strategy
  January 9, 2026

• BUSINESS Asahi Kasei Sees Tarpeyo Uptake Outpacing Forecast, Peak Sales Can Be Higher
  January 9, 2026

• BUSINESS Rakuten Ramps Up Photoimmunotherapy PIII with Financing, Eyes US Filing in 2028
  January 9, 2026

• BUSINESS Shionogi’s Antibiotic Cefiderocol Approved in China
  January 9, 2026

• BUSINESS Mochida’s EPA Drug Epadel S Wins Approval in China
  January 9, 2026

• BUSINESS Keytruda Tops Japan Drug Sales Again in December, Marking 27-Month Run: Encise
  January 9, 2026

• BUSINESS Hisamitsu to Go Private in Management Buyout Valued at 400 Billion Yen
  January 8, 2026

• BUSINESS AbbVie Introduces No-Relocation Work Option for Sales Staff
  January 8, 2026

ページ

• « 先頭
• ‹ Prev
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »